Portal de Periódicos da CAPES

Autoimmune hepatitis: The investigational and clinical challenges

2000; Lippincott Williams & Wilkins; Volume: 31; Issue: 5 Linguagem: Inglês

10.1053/he.2000.5980

1527-3350

Albert J. Czaja, Michawl P. Manns, Ian G. McFarlane, Jay H. Hoofnagle,

Pediatric Hepatobiliary Diseases and Treatments

HepatologyVolume 31, Issue 5 p. 1194-1200 Meeting ReportFree Access Autoimmune hepatitis: The investigational and clinical challenges Albert J. Czaja, Corresponding Author Albert J. Czaja czaja.albert@mayo.edu Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MNMayo Clinic, 200 First Street S.W., Rochester, MN 55905. fax: 507-284-0538===Search for more papers by this authorMichawl P. Manns, Michawl P. Manns Medical School of Hannover, Hannover, GermanySearch for more papers by this authorIan G. Mcfarlane, Ian G. Mcfarlane King's College Hospital, London, United KingdomSearch for more papers by this authorJay H. Hoofnagle, Jay H. Hoofnagle National Institutes of Health, Bethesda, MDSearch for more papers by this author Albert J. Czaja, Corresponding Author Albert J. Czaja czaja.albert@mayo.edu Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MNMayo Clinic, 200 First Street S.W., Rochester, MN 55905. fax: 507-284-0538===Search for more papers by this authorMichawl P. Manns, Michawl P. Manns Medical School of Hannover, Hannover, GermanySearch for more papers by this authorIan G. Mcfarlane, Ian G. Mcfarlane King's College Hospital, London, United KingdomSearch for more papers by this authorJay H. Hoofnagle, Jay H. Hoofnagle National Institutes of Health, Bethesda, MDSearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/he.2000.5980Citations: 49AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Rose NR. Pathogenic mechanisms in autoimmune diseases. Clin Immunol Immunopathol 1989; 53: S7– S16.MEDLINE 2 Tan EM, Chan EK, Sullivan KF, Rubin RL. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol 1988; 47: 121– 141.MEDLINE 3 Meyer zum Buschenfelde K-H, Lohse AW, Manns M, Poralla T. Autoimmunity and liver disease. Hepatology 1990; 12: 354– 363.MEDLINE 4 Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child 1992; 67: 1447– 1453.MEDLINE 5 Lobo-Yeo A, Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990; 12: 224– 232.MEDLINE 6 Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34– 38.MEDLINE 7 Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264– 274.MEDLINE 8 Al-Wabel A, Al-Janadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic active hepatitis. J Allergy Clin Immunol 1993; 92: 902– 908.MEDLINE 9 Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-α in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 1995; 20: 23– 27.MEDLINE 10 Ismail NE, Portmann BC, Hussain M, Williams R, Mieli-Vergani G, Vergani D. Immunohistochemical evidence for Th1 cytokine predominance in the liver of children with autoimmune hepatitis [Abstract]. Hepatology 1999; 30: 428A. 11 Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci, in press. 12 Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701– 706.MEDLINE 13 Strettell MDJ, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112: 2028– 2035.MEDLINE 14 Czaja AJ, Strettell MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317– 323.MEDLINE 15 Donaldson PT, Manns MP. Immunogenetics of liver disease. In: J Bircher J-P, N Benhamou, M McIntyre, J Rizzetto, Rodes eds. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1999; 173– 188. 16 Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev, in press. 17 Seki T, Kiyosawa K, Inoko H, Ota M. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990; 12: 1300– 1304.MEDLINE 18 Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, Badia I, et al. Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999; 30: 1374– 1380.MEDLINE 19 Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Carrilho FJ, Farias AQ, Palacios SA, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999; 94: 1906– 1913.MEDLINE 20 Vazquez-Garcia MN, Alaez C, Olivo A, Debaz H, Perez-Luque E, Burguete A, Cano S, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998; 28: 985– 990.MEDLINE 21 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502– 1507.MEDLINE 22 Chicz RM, Urban RG, Gorga JC, Vignall DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to DLA-DR alleles. J Exp Med 1993; 178: 27– 47.MEDLINE 23 Hammer J, Valsasnini P, Tolba K, Bollin D, Higelin J, Takacs B, Sinigaglia F. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1993; 74: 197– 203.MEDLINE 24 Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994; 19: 609– 615.MEDLINE 25 Doherty DG, Penzotti JE, Koelle DM, Kwok WW, Lybrand TP, Masewicz S, Nepom GT. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 1998; 161: 3527– 3535.MEDLINE 26 Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999; 117: 645– 652.MEDLINE 27 Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000; 31: 49– 53.MEDLINE 28 Parish N, Hutchings P, O'Reilly L, Quartey-Papafio R, Healey D, Ozegbe P, Cooke A. Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Immunol Rev 1995; 144: 169– 300. 29 Milich DR, Schodel F, Peterson DL, Lones JE, Hughes JL. Characterization of self-reactive T cells that evade tolerance in HBeAg transgenic mice. Eur J Immunol 1995; 25: 1663– 1672.MEDLINE 30 Czaja AJ. Chronic graft-versus-host disease and primary biliary cirrhosis: sorting the puzzle pieces [Editorial]. Lab Invest 1994; 70: 589– 592.MEDLINE 31 Lohse AW. Experimental models of autoimmune hepatitis. Semin Liver Dis 1991; 11: 241– 247.MEDLINE 32 Manns MP, Obermayer-Straub P. Viral induction of autoimmunity: mechanisms and examples in Hepatology. J Viral Hepat 1997; 4(Suppl 2): 42– 47.MEDLINE 33 Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KM, Reichen J, Melief CJ, et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999; 190: 169– 176.MEDLINE 34 Mason AL, Xu L, Guo L, Garry RF. Retroviruses in autoimmune liver disease: genetic or environmental agents? Arch Immunol Ther Exp 1999; 47: 289– 297. 35 Mason A, Xu L, Guo L, Munoz S, Jaspan JB, Bryer-Ash M, Cao Y, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998; 351: 1620– 1624.MEDLINE 36 von Herrath MG, Oldstone MBA. Virus-induced autoimmune disease. Curr Opin Immunol 1996; 8: 878– 885.MEDLINE 37 Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH, De Virgiliis S, et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1997; 82: 1353– 1361.MEDLINE 38 Johnson PJ, McFarlane IG, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, Chapman RW, et al. Meeting Report. International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998– 1005.MEDLINE 39 International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929– 938.MEDLINE 40 Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996; 41: 305– 314.MEDLINE 41 Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995; 90: 1206– 1211.MEDLINE 42 Labrecque DR, Phillips MJP, Ippolito LA, Mitros FA, Goeken JA. Antineutrophil cytoplasmic antibody and chronic liver disease [Abstract]. Hepatology 1999; 30: 428A. 43 Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999; 30: 394– 401.MEDLINE 44 Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996; 125: 588– 598.MEDLINE 45 Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360– 365.MEDLINE 46 Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, Mowat AP, et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 1997; 25: 541– 547.MEDLINE 47 Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988; 95: 448– 453.MEDLINE 48 Czaja AJ. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999; 57: 49– 68.MEDLINE 49 Lohse AW, Dienes HP, Meyer zum Buschenfelde K-H. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998; 27: 1536– 1543.MEDLINE 50 Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999; 48: 106– 119.MEDLINE 51 Utku N, Heinemann T, Tullius SG, Bulwin GC, Beinke S, Blumberg RS, Beato F, et al. Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity 1998; 9: 509– 518.MEDLINE Citing Literature Volume31, Issue5May 2000Pages 1194-1200 ReferencesRelatedInformation